Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Clinical trial NCT05258279 · COMPLETED

Trial details

NCT number: NCT05258279
Sponsor: Juntendo University
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-squamous Non-small-cell Lung Cancer EGFR Activating Mutation

Start date: 2022-07-01
Primary completion: 2023-10-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.